CTLA-4 blockade generates greater memory response than PD-1 blockade
Immune checkpoint inhibitors targeting CTLA-4 and PD-1, which stimulate the body’s own T cells to eliminate cancer, are an efficient treatment strategy for many cancers. Notably, CTLA-4 blockade seemingly leads to more durable responses compared to PD-1 blockade. Some studies suggest this could be attributed to differing memory CD8 T cell responses from each strategy, but the mechanisms remain unclear. In a new study, researchers led by Stephen Mok, Ph.D., and James Allison, Ph.D., used tumor...











